Residency · Residency · Pathology

Bladder Pathology and Urothelial Carcinoma

Overview

Urothelial carcinoma is the most common bladder malignancy and the pathologist's role in grading, staging, and variant histology recognition directly impacts clinical management. The presence or absence of muscularis propria in transurethral resection specimens is a critical quality metric.

Normal Urothelium

The bladder is lined by transitional epithelium (urothelium) that is 3 to 7 cell layers thick. The surface is composed of umbrella cells, which are large superficial cells with eosinophilic cytoplasm that are CK20-positive. Beneath these are intermediate and basal cells. Within the lamina propria lies the muscularis mucosae, a thin and discontinuous smooth muscle layer that must not be confused with the muscularis propria. The muscularis propria (detrusor muscle) consists of thick muscle bundles and is essential for accurate staging.

Flat Urothelial Lesions

Reactive Urothelial Atypia

Reactive atypia occurs in an inflammatory background and shows nuclear enlargement with a preserved nuclear-to-cytoplasmic ratio. Nuclear contours remain smooth and chromatin is uniform. Prominent nucleoli are a reactive feature. Mitoses may be present but are confined to the lower layers of the epithelium. CK20 expression is limited to umbrella cells, reflecting the normal staining pattern.

Urothelial Carcinoma In Situ (CIS)

CIS presents as full-thickness or partial-thickness severe cytologic atypia of flat urothelium. The cells have large, pleomorphic nuclei with irregular contours, hyperchromasia, and a high nuclear-to-cytoplasmic ratio. There is loss of cell polarity and the cells are dyscohesive, which may cause them to shed into urine. CK20 shows diffuse full-thickness staining, which is abnormal since it is normally limited to umbrella cells. p53 demonstrates an aberrant pattern (diffuse overexpression or complete null), and CD44 expression is lost (normally positive in basal and intermediate cells). CIS carries a high risk of progression to invasive carcinoma if untreated, is often multifocal, and may be concurrent with papillary or invasive carcinoma.

Papillary Urothelial Neoplasms

Urothelial Papilloma

Urothelial papilloma is a benign lesion with papillary architecture lined by normal urothelium without atypia, supported by thin fibrovascular cores. It is very rare in adults and carries an excellent prognosis with no recurrence risk.

Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP)

PUNLMP shows papillary architecture with thickened urothelium but minimal cytologic atypia. Cellular arrangement remains ordered and mitoses are rare. The recurrence rate is low with essentially no progression to invasion. This remains a controversial entity, with some authorities considering it equivalent to low-grade papillary carcinoma.

Low-Grade Papillary Urothelial Carcinoma

Low-grade papillary urothelial carcinoma exhibits papillary architecture with mild-to-moderate cytologic atypia, including some variation in nuclear size, shape, and chromatin. Cellular organization is maintained and mitoses occur only in the lower half. It recurs frequently (50 to 70 percent) but carries a low risk of progression to invasion (approximately 5 percent).

High-Grade Papillary Urothelial Carcinoma

High-grade papillary urothelial carcinoma shows marked cytologic atypia with nuclear pleomorphism, hyperchromasia, and irregular nuclear contours. There is loss of cell polarity with full-thickness atypia and frequent mitoses at all levels of the epithelium. The recurrence rate is high with a significant risk of invasion and progression (15 to 40 percent). Molecularly, FGFR3 mutations are less common while TP53 and RB1 alterations are more frequent.

Invasive Urothelial Carcinoma

Staging -- Critical for Management

T1 (Lamina Propria Invasion)

T1 disease involves invasion through the basement membrane into the lamina propria (subepithelial connective tissue) without involvement of the muscularis propria. This can be challenging to diagnose; the pathologist should look for single cells, nests, or cords infiltrating within a desmoplastic stroma. Retraction artifact around invasive nests can mimic lymphovascular invasion. Paradoxical differentiation may occur where invasive cells appear more differentiated than the surface component.

T1 Substaging (Controversial)

T1 substaging divides lamina propria invasion into T1a (invasion above the muscularis mucosae) and T1b (invasion into or beyond the muscularis mucosae). This substaging is recommended by some experts but not universally adopted due to reproducibility concerns. Both the depth and extent of invasion correlate with recurrence and progression risk.

T2 (Muscularis Propria Invasion)

T2 disease is subdivided into T2a (inner half of muscularis propria) and T2b (outer half of muscularis propria). The presence of muscularis propria in the TUR specimen is essential for accurate staging. If no muscularis propria is present, this must be explicitly reported and re-resection is recommended to exclude understaging.

Muscularis Propria vs. Muscularis Mucosae

The muscularis mucosae consists of thin, wispy, discontinuous smooth muscle bundles within the lamina propria. The muscularis propria (detrusor) is composed of thick, organized bundles of smooth muscle. This distinction is critical because tumor invading only the muscularis mucosae remains T1. Smoothelin IHC may help in difficult cases, as it is strongly positive in muscularis propria and weakly positive or negative in muscularis mucosae.

Variant Histology

Squamous Differentiation

Squamous differentiation is the most common variant, characterized by keratinization and intercellular bridges within urothelial carcinoma. It is associated with poor response to chemotherapy. Pure squamous cell carcinoma of the bladder is associated with chronic irritation from schistosomiasis or chronic catheterization.

Glandular Differentiation

Glandular differentiation manifests as gland-forming areas within urothelial carcinoma, often with an enteric (colonic) pattern and mucin production. It must be distinguished from primary bladder adenocarcinoma and urachal adenocarcinoma.

Micropapillary Variant

The micropapillary variant shows small tight clusters of cells in lacunar spaces created by retraction artifact, resembling ovarian serous micropapillary pattern. It is highly aggressive with a high rate of lymphovascular invasion and lymph node metastasis. It is often understaged on TUR, and early cystectomy is recommended even for T1 disease.

Small Cell/Neuroendocrine Carcinoma

This variant is identical to pulmonary small cell carcinoma and is positive for synaptophysin, chromogranin, and CD56, with TTF-1 sometimes positive. Neuroendocrine-directed chemotherapy (cisplatin/etoposide) is indicated along with early cystectomy.

Plasmacytoid Variant

The plasmacytoid variant consists of discohesive cells resembling plasma cells with eccentric nuclei and eosinophilic cytoplasm. It infiltrates in a single-cell or linear pattern and tends toward diffuse peritoneal spread. E-cadherin is lost due to CDH1 mutations, mimicking lobular breast carcinoma. Margin detection is difficult and prognosis is poor.

Sarcomatoid Variant

The sarcomatoid variant is biphasic with carcinomatous and sarcomatous components. It may contain heterologous elements such as osteosarcoma, chondrosarcoma, or rhabdomyosarcoma. It is very aggressive with a poor prognosis.

Nested Variant

The nested variant shows deceptively bland-appearing nests of urothelial cells in the lamina propria that closely mimic von Brunn nests. The key to diagnosis lies in recognizing irregular nest size, stromal reaction, and cytologic atypia at deeper levels. Despite its bland appearance, behavior is aggressive.

Reporting Requirements for TUR Specimens

The pathology report for TUR specimens must include histologic type and grade (low-grade versus high-grade), presence and extent of invasion (non-invasive, T1, or T2), variant histology (type and percentage), lymphovascular invasion, presence of concurrent CIS, and the presence of muscularis propria in the specimen. If muscularis propria is absent, this must be explicitly stated with a recommendation for re-resection.

<image>A medical illustration of urothelial carcinoma grading and CIS. Panel A (Normal urothelium): Orderly layered transitional epithelium with umbrella cells at the surface, CK20 IHC showing staining limited to umbrella cells only. Panel B (Low-grade papillary urothelial carcinoma): Papillary fronds lined by urothelium with mild nuclear atypia, maintained organization, and rare mitoses. Panel C (High-grade papillary urothelial carcinoma): Papillary architecture with marked nuclear pleomorphism, loss of polarity, and frequent mitoses at all levels. Panel D (CIS): Flat urothelium with full-thickness severe cytologic atypia, dyscohesive cells, CK20 IHC showing diffuse full-thickness staining pattern (abnormal), p53 IHC showing diffuse strong overexpression.</image>

<image>A medical illustration of urothelial carcinoma staging in TUR specimens. Panel A (Non-invasive, Ta): Papillary tumor confined to the urothelium, no invasion through the basement membrane. Panel B (T1, lamina propria invasion): Irregular nests and cords of tumor cells invading into lamina propria with desmoplastic stromal response, muscularis mucosae visible as thin muscle bundles. Panel C (T2, muscularis propria invasion): Tumor infiltrating between thick bundles of muscularis propria (detrusor muscle). Panel D: Comparison of muscularis mucosae (thin, wispy, discontinuous bundles in lamina propria) versus muscularis propria (thick, organized muscle bundles), with smoothelin IHC showing strong staining in detrusor muscle and weak/absent staining in muscularis mucosae.</image>

<image>A medical illustration of urothelial carcinoma variant histologies. Panel A (Micropapillary variant): Small tight tumor cell clusters floating in clear lacunar spaces, resembling ovarian serous micropapillary carcinoma. Panel B (Plasmacytoid variant): Single discohesive cells with eccentric nuclei and eosinophilic cytoplasm infiltrating in a linear pattern, E-cadherin IHC inset showing loss of membranous staining. Panel C (Small cell variant): Sheets of small cells with scant cytoplasm, nuclear molding, and crush artifact, synaptophysin IHC inset positive. Panel D (Nested variant): Deceptively bland-appearing nests of urothelial cells infiltrating lamina propria, mimicking von Brunn nests, with irregular nest sizes and subtle stromal reaction at deeper levels.</image>

Clinical Pearls

The presence of muscularis propria (detrusor muscle) in TUR specimens must be explicitly reported; if absent, the tumor cannot be reliably staged and re-resection is indicated. This is a quality metric for urologic pathology reporting. Micropapillary variant urothelial carcinoma is clinically understaged in 40 to 60 percent of TUR cases; even T1 micropapillary carcinoma on TUR warrants consideration for early cystectomy due to the high rate of occult advanced disease.

The nested variant is the most commonly misdiagnosed urothelial carcinoma variant because it closely mimics benign von Brunn nests. The pathologist should look for irregular nest contour, confluence at depth, and any cytologic atypia, as these cases are aggressive despite bland morphology. CK20 and p53 IHC are valuable in distinguishing reactive urothelial atypia from CIS: CIS shows diffuse full-thickness CK20 staining and aberrant p53 (overexpression or null), while reactive atypia shows CK20 limited to umbrella cells and wild-type p53.

All variant histologies should be reported with their percentage because they influence treatment decisions. Squamous and glandular differentiation may predict poor response to cisplatin-based chemotherapy, while small cell differentiation changes the entire treatment paradigm to neuroendocrine-directed chemotherapy. T1 substaging, while not universally adopted, is increasingly recommended; depth of lamina propria invasion and presence of lymphovascular invasion are the strongest predictors of progression in T1 disease.

References

• WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. 5th ed. IARC; 2022.
• Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs. Eur Urol. 2016;70(1):106-119.
• Amin MB, et al. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
• Comperat E, et al. Grading of urothelial carcinoma and the new "World Health Organisation classification of tumours of the urinary system and male genital organs 2016." Eur Urol Focus. 2019;5(3):457-466.
• Willis DL, et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015;193(4):1129-1134.

Read this lecture as Markdown